CD20-positive B-cell depletion is a highly promising treatment for multiple sclerosis (MS),
but the mechanisms underlying therapeutic effects are poorly understood. B cells are …

Background Clinical trials evaluating anti-CD20-mediated B-cell depletion in multiple
sclerosis (MS) and neuromyelitis optica (NMO) generated encouraging results. Our recent …

B cells are increasingly regarded as integral to the pathogenesis of multiple sclerosis, in part
as a result of the success of B cell–depletion therapy. Multiple B cell–dependent …

Depletion of CD20+ B cells has been related to reduced clinical activity in relapsing–
remitting multiple sclerosis. The underlying mechanism is not understood, because serum …

This study investigated the effect of CD20-positive B-cell depletion on central nervous
system (CNS) white and gray matter pathology in experimental autoimmune …

Objective Clinical studies indicate that anti‐CD20 B‐cell depletion may be an effective
multiple sclerosis (MS) therapy. We investigated mechanisms of anti‐CD20‐mediated …

Background The human myelin oligodendrocyte glycoprotein-induced experimental
autoimmune encephalomyelitis (huMOG-EAE) model, generates B-cell driven demyelination …

Background Clinical studies of B cell depletion in Multiple Sclerosis (MS) have revealed that
B Lymphocytes are involved in the neuro-inflammatory process, yet it remains unclear how B …

The contribution of autoantibody-producing plasma cells in multiple sclerosis (MS) remains
unclear. Anti-CD20 B cell depletion effectively reduces disease activity in MS patients, but it …

The efficacy of rituximab treatment in multiple sclerosis has renewed interest in the role of B
cells in CNS autoimmunity. In this study, we show that B cells are the predominant MHC …